Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00237458
Status:
COMPLETED
Last Update Posted:
2017-08-28
First Post:
2005-10-11
Brief Title:
An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic Pain
Sponsor:
UCB Pharma
Organization:
UCB Pharma
Study Overview
Official Title:
An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic Pain
Status:
COMPLETED
Status Verified Date:
2017-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is the follow-on trial to a preceeding open-label trial which included patients with chronic refractory neuropathic pain It is conducted at one site in the United Kingdom and the patient enrollment is completed The patients had successfully completed the above mentioned trial and in the investigators opinion would benefit from long-term administration of Lacosamide After a 1-week run-in phase the patients were uptitrated to their optimal dose and then continued into the maintenance phase Different pain qualities are assessed by a patients diary
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None